Plus Therapeutics, Inc. has begun treating patients in its ReSPECT-LM dose optimization trial for REYOBIQ (rhenium Re186 obisbemeda), targeting leptomeningeal metastases (LM), a severe complication of ...
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
Reinforcement Learning, Explainable AI, Computational Psychiatry, Antidepressant Dose Optimization, Major Depressive Disorder, Treatment Personalization, Clinical Decision Support Share and Cite: de ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback